OnCusp Therapeutics, Inc., headquartered in New York City, is a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. OnCusp was co-founded by Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu, and has built a strong team of accomplished veterans with proven track records in building startup biotechs, leading successful preclinical and clinical programs, and creating value through global partnerships. The company is committed to accelerating the advancement of globally competitive oncology assets for patients.
Location: United States, New York
Employees: 11-50
Total raised: $100M
Founded date: 2021
Investors 3
| Date | Name | Website |
| - | F-Prime Ca... | fprimecapi... |
| 27.05.2024 | Sofinnova ... | sofinnova.... |
| 30.01.2024 | Catalio Ca... | cataliocap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.01.2024 | Series A | $100M | - |
Mentions in press and media 11
| Date | Title | Description |
| 14.05.2026 | OnCusp Therapeutics Appoints Anthony Kim as Chief Financial Officer | PRINCETON, N.J., May 14, 2026 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company developing differentiated oncology therapies designed to translate cutting-edge innovation into clinically meaningful outcom... |
| 23.06.2025 | OnCusp Therapeutics Appoints Dimitry Nuyten, M.D., Ph.D., as Chief Medical Officer | PRINCETON, N.J., June 23, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, tod... |
| 02.06.2025 | OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovar... | CUSP06 is a CDH6-directed ADC with a differentiated profile and potentially best-in-class activity CUSP06 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor ADCs Promising signs of efficacy were observed in patie... |
| 06.03.2024 | OnCusp Therapeutics Announces First Patient Dosed in Phase 1 Trial of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors | - |
| 09.01.2024 | Deals in brief: Atome raises USD 31 million from parent firm, Asia Partners closes second fund, multiple China and India deals, and more | Atome raises USD 31 million from parent firm The Singapore-based fintech company has raised USD 31 million from Advance Intelligence Group, its parent company. According to Tech in Asia, Atome said the capital is a result of internal share ... |
| 08.01.2024 | Deals in brief: Semaai, Komunal, and OnCusp secure funding, Etherscan acquires Solscan, multiple China and India deals, and more | Semaai raises USD 4.7 million in pre-Series A round The Indonesian agritech startup has raised USD 4.7 million in a pre-Series A funding round, featuring a mix of debt and equity financing. CyberAgent Capital, a Japan-based early-stage corp... |
| 05.01.2024 | OnCusp Therapeutics secures $100m to advance cancer treatment | InvestmentsNews Lokesh Choudhary · 1d ago · 1 min readOnCusp Therapeutics secures $100m to advance cancer treatment Photo credit: CDC on Unsplash OnCusp Therapeutics has raised US$100 million in a series A round co-led by Novo Holdings, Orb... |
| 04.01.2024 | OnCusp Therapeutics Raises Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients | - |
| 11.04.2023 | OnCusp Therapeutics Showcases Potent Anti-Tumor Activity of its CDH6 ADC at AACR Annual Meeting 2023 | SHENZHEN, China, April 11, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today ... |
| 30.06.2021 | OnCusp Therapeutics Commences Operations to Advance Innovative Oncology Therapies | NEW YORK, June 30, 2021 /PRNewswire/ -- OnCusp Therapeutics (or "OnCusp"), a global biopharmaceutical company focused on translating cutting-edge research assets into innovative oncology therapeutics, announced that it has officia... |
Show more